Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 2

Not yet recruiting

• Conditions: Triple-Negative Breast Cancer (TNBC)
• Interventions: Drug: QL1706 Plus Olaparib

• Registration Number: NCT07005583
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring homologous recombination repair deficiency (HRD) who have received prior therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-12
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-03
• Last Update Submitted: 2025-06-03
• Study First Posted: 2025-06-05
• Last Update Posted: 2025-06-05
• Study Start: 2025-06-30
• Primary Completion: 2027-05-30
• Study Completion: 2030-05-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 46

Inclusion Criteria

1. Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.
2. Female breast cancer patients aged ≥18 and ≤75 years, with histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer (TNBC) as defined by the latest ASCO/CAP guidelines (based on the most recent biopsy or other pathological specimens).
3. Have received at least 1 but no more than 2 prior lines of anti-tumor therapy （ Disease progression during or within 12 months after completing neoadjuvant/adjuvant therapy counts as one line of therapy；Must have received taxane-based therapy at any stage；A maximum of 1 prior antibody-drug conjugate (ADC) therapy is allowed.）
4. Documented homologous recombination repair deficiency (HRD) (BRCA1/2 mutation and/or HRD-positive status.
5. Any PD-L1 expression status (no restriction).
6. Have at least one measurable lesion according to RECIST 1.1 criteria (assessed by CT or MRI). Bone-only lesions are considered non-measurable and do not qualify for enrollment.
7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
8. Availability of tumor tissue samples for biomarker testing.
9. Ability to swallow tablets normally.
10. Expected survival ≥3 months.
11. Presence of adequate bone marrow and organ function.

Exclusion Criteria

1. Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4) or PARP inhibitors (e.g., olaparib, niraparib).
2. Current use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment.
3. History of severe allergic reactions to monoclonal antibodies.
4. Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.
5. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis.
6. History of CNS metastases or current CNS metastases. Baseline imaging to confirm absence of brain metastases is not mandatory. Patients with unknown CNS status but clinical signs suggestive of CNS involvement are eligible if CNS metastases are ruled out by CT/MRI.
7. History of other malignancies (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless disease-free for ≥3 years.
8. Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) despite antihypertensive therapy. History of hypertensive crisis or hypertensive encephalopathy.
9. History of unstable angina, myocardial infarction, chronic heart failure (LVEF <50%), or clinically significant arrhythmias requiring treatment (except stable atrial fibrillation) within 6 months prior to treatment.
10. Current therapeutic anticoagulation or thrombolysis (prophylactic low-dose aspirin/LMWH permitted).
11. Clinically significant effusions (pleural, peritoneal, or pericardial) requiring drainage, unless stabilized post-drainage per investigator assessment.
12. Arterial/venous thromboembolic events (e.g., CVA, TIA, DVT, PE) within 6 months prior to enrollment.
13. Major vascular disease (e.g., aortic aneurysm requiring repair or recent peripheral arterial thrombosis) within 6 months.
14. Major surgery within 4 weeks prior to treatment or anticipated during the study (excluding diagnostic procedures).
15. Urine protein ≥++ on dipstick with confirmed 24-hour urine protein >1.0 g.
16. Prior radiotherapy (except palliative bone radiation), chemotherapy, or surgery (excluding biopsy) within 4 weeks before treatment initiation; <4 weeks since last antibody therapy; <5 half-lives since last targeted therapy (including investigational agents); or unresolved toxicities (>CTCAE grade 1, except alopecia).
17. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.
18. Immunodeficiency (e.g., HIV); HBsAg-positive with HBV DNA ≥2000 IU/mL; or HCV antibody-positive.
19. Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma resolved without intervention, or stable hypothyroidism on hormone replacement.
20. Live vaccination within 4 weeks prior to treatment or planned during the study.
21. Planning pregnancy, pregnancy, or suckling period;
22. The investigator judged that the patients are not suitable for participating in this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
QL1706 + Olaparib	QL1706 Plus Olaparib	-

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS) - investigator assessment	Up to 2 years

Secondary Outcome Measures

Name	Time	Method
Objective response rate (ORR) - Investigator assessment	Up to 2 years
Duration of response (DOR) - Investigator assessment	Up to 2 years
Overall survival (OS)	Up to 5 years
Number of participants with adverse events (AEs), Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)	Up to 5 years

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital; 🇨🇳 Tianjin, China